<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518427</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4057</org_study_id>
    <secondary_id>Eudract #: 2005-000959-15</secondary_id>
    <nct_id>NCT00518427</nct_id>
  </id_info>
  <brief_title>Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine</brief_title>
  <acronym>QoL</acronym>
  <official_title>A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To assess quality of Life (QoL) changes and treatment satisfaction in a real life situation&#xD;
      in patients with Type 2 diabetes inadequately controlled on a combination of oral&#xD;
      antidiabetic drugs (OAD) plus Neutral Protamine Hagedrone (NHP) insulin treatment that are&#xD;
      switched to insulin glargine.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      To determine:&#xD;
&#xD;
      change in HbA1c, comparision of the incidence of symptomatic hypoglycemia and severe&#xD;
      hypoglycemia before and after introduction of insulin glargine, change in weight, change in&#xD;
      insulin dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The fear of hypoglycaemia scale (HFS)</measure>
    <time_frame>before the switch to insulin glargine and at 3 and 9 months of follow up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 - Item Well-Being Questionnaaire (WBQ12)</measure>
    <time_frame>before the switch to insulin glargine and at 3 and 9 months of follow up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycaemic controll will be asessed by HbA1c values</measure>
    <time_frame>week 12 and week 40</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic hypoglycemia and severe hypoglycemia</measure>
    <time_frame>sreening to follow-up phases</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.&#xD;
Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        lists of inclusion and exclusion criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2diabetes inadequately controlled on a combination of OAD + NPH&#xD;
             insulin for more than three months&#xD;
&#xD;
          -  Stable OAD therapy for at least three months, according to the following specified&#xD;
             daily dose: glibenclamide&gt; 3, 5 mg, glipizid &gt;5 mg, glimeperid &gt;2mg, metformin&gt;1000&#xD;
             mg, acarbose &gt;150 mg&#xD;
&#xD;
          -  HbA1c &gt; 7,0%&#xD;
&#xD;
          -  Ability to perform QoL assessment&#xD;
&#xD;
          -  Body Mass Indes: women &lt;30 and men &lt;32&#xD;
&#xD;
        Exlusion criteria:&#xD;
&#xD;
          -  Autoimmune diabetes, as defined by WHO&#xD;
&#xD;
          -  Ongoing treatment with tiasolidindion drug&#xD;
&#xD;
          -  Retinopathy with surgical treatment during preceding three months of study entry or&#xD;
             requiring treatment within three months after study entry&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Hypersensitivity to insulin glagine excipients&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margareta Olsson-Birgersson</last_name>
    <role>Study Director</role>
    <affiliation>sanofi-aventis, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

